Currently 940 clinical stage immuno-oncology agents being developed, report

The USA-based Cancer Research Institute (CRI) last week published a report that provides a first-of-its-kind independent analysis of the global immuno-oncology (I-O) landscape, from agents in pre-clinical development to regulatory approval.

The report quantifies a significant number of I-O agents in development and this level of activity will likely result in an unparalleled number of advances in the field - but it also creates some challenges

The report, titled, “Comprehensive Analysis of the Immuno-Oncology Landscape,” published online in the Annals of Oncology, ESMO’s official journal, highlights findings from an analysis of CRI's robust, scientifically-curated database that actively tracks 2,004 I-O agents, of which 940 are already in clinical development.

“This is the first independent analysis that quantifies and confirms the level of excitement and potential of immuno-oncology,” said Aiman Shalabi, CRI’s chief medical officer and director of the Anna-Maria Kellen Clinical Accelerator, a non-profit, philanthropic venture capital fund. “Today, we are incredibly fortunate to see so much progress for patients, and the science will continue to rapidly evolve. By using these landscape data, we aim to better inform the field and find solutions to several meaningful and actionable trends in the current IO landscape,” she noted.

11-12-2017

https://www.thepharmaletter.com/